Teva Indices is a technology company.
Teva Indices develops precise indices quickly for the creation of the most efficient ETFs in the Brazilian market, focusing on investment theses.
Teva Indices has raised $3.5M across 2 funding rounds.
Teva Indices has raised $3.5M in total across 2 funding rounds.
Teva Pharmaceutical Industries Ltd, commonly known as Teva, is a global leader in generic medicines, specialty biopharmaceuticals, and biosimilars, not a technology company focused on indices or software.[1] Headquartered in Tel Aviv, Israel, it develops, manufactures, and delivers these products to customers worldwide from 61 manufacturing facilities across 60 countries, employing about 35,125 people and generating USD 15.9 billion in revenue as a publicly listed company.[1] Teva serves healthcare providers, pharmacies, and patients by providing affordable generics—the world's largest supplier—and innovative treatments for complex diseases like multiple sclerosis and cancer, addressing the critical need for accessible, high-quality pharmaceuticals amid rising drug costs and patent expirations.[1]
Teva traces its roots to 1901 in Israel, evolving from early pharmaceutical operations into a modern multinational powerhouse still headquartered in Tel Aviv.[1] Founded amid the challenges of pre-state Israel, it grew through mergers and expansions, notably becoming the generic drug giant it is today by aggressively pursuing cost-effective production and global market penetration. Pivotal moments include its 1980s push into the U.S. generics market and subsequent acquisitions like Barr Laboratories in 2008, which solidified its dominance despite later debt challenges from overexpansion.[1]
Teva stands out in the pharmaceutical industry through these key strengths:
While primarily pharmaceutical, Teva intersects the tech landscape through biotech advancements like AI-driven drug discovery, precision manufacturing, and digital supply chains—trends accelerating post-2020 amid biotech funding booms.[1] Its timing aligns with global pressures for affordable drugs amid aging populations and biosimilar patent cliffs (e.g., Humira equivalents), where market forces like U.S. inflation Reduction Act incentives favor generics giants. Teva influences the ecosystem by pressuring originators on pricing, fostering competition that lowers costs and expands access, while its Israeli roots tie into the nation's "Startup Nation" biotech hub, exporting innovation globally.[1][2]
Teva is poised for recovery through debt reduction, biosimilars growth, and generics stabilization, with tailwinds from AI-optimized R&D and emerging markets expansion. Trends like personalized medicine and supply chain digitization will shape its path, potentially elevating its influence as a hybrid pharma-tech player. As the original affordable drug pioneer, Teva's scale positions it to dominate the next wave of accessible biotech, delivering value in a high-cost healthcare world.[1]
Teva Indices has raised $3.5M in total across 2 funding rounds.
Teva Indices's investors include 1984 Ventures, Amplo, Bascom Ventures, Caravela Capital, Contrary Capital, DGF Investimentos, DN Capital, Honey Island Capital, Lakestar, SV Angel, Turtle Ventures, Unpopular Ventures.
Teva Indices has raised $3.5M across 2 funding rounds. Most recently, it raised $3.0M Series A in June 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2023 | $3.0M Series A | 1984 Ventures, Amplo, Bascom Ventures, Caravela Capital, Contrary Capital, DGF Investimentos, DN Capital, Honey Island Capital, Lakestar, SV Angel, Turtle Ventures, Unpopular Ventures, Urban Innovation Fund, Ed Baker, Oliver Jung | |
| Feb 1, 2022 | $470K Seed | Darwin Startups |